

**CHANGE - ANNOUNCEMENT OF CESSATION::RESIGNATION OF CHIEF FINANCIAL OFFICER**

## Issuer &amp; Securities

## Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

## Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

## Stapled Security

No

## Announcement Details

## Announcement Title

Change - Announcement of Cessation

## Date &amp; Time of Broadcast

06-May-2022 19:12:23

## Status

New

## Announcement Sub Title

Resignation of Chief Financial Officer

## Announcement Reference

SG220506OTHRFBK

## Submitted By (Co./ Ind. Name)

Lim See Wah

## Designation

Executive Chairman and Chief Executive Officer

## Description (Please provide a detailed description of the event in the box below)

This announcement has been reviewed by the Company's Sponsor, SAC Capital Private Limited (the "Sponsor"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Lee Khai Yinn (Tel: +65 6232 3210) at 1 Robinson Road, #21-00 AIA Tower, Singapore 048542.

## Additional Details

## Name Of Person

Fang Lee Wei

## Age

47

## Is effective date of cessation known?

Yes

## If yes, please provide the date

13/06/2022

## Detailed Reason (s) for cessation

Ms Fang Lee Wei ("Ms Fang") has resigned as the Chief Financial Officer ("CFO") to pursue other career opportunities.

After having interviewed Ms Fang and to the best of its knowledge, the Company's Sponsor, SAC Capital Private Limited, is satisfied that, other than as disclosed in this announcement, there are no other material reasons for the resignation of Ms Fang as CFO.

There are no concerns with regards to the financial reporting that led to the departure of Ms Fang and there are no disagreements between Ms Fang and the Board of the Company with regards to practices that

will have an impact on the Company's financial reporting.

Whilst the Company is in the midst of identifying a replacement and will make the necessary announcement in due course, Mr Lim See Wah, Executive Chairman & CEO shall oversee the Group's financial management during this period and he will be assisted by Ms Serene Lim, Finance Director.

---

Are there any unresolved differences in opinion on material matters between the person and the board of directors, including matters which would have a material impact on the group or its financial reporting?

No

---

Is there any matter in relation to the cessation that needs to be brought to the attention of the shareholders of the listed issuer?

No

---

Any other relevant information to be provided to shareholders of the listed issuer?

No

---

Date of Appointment to current position

01/01/2016

---

Does the AC have a minimum of 3 members (taking into account this cessation)?

Yes

---

Number of Independent Directors currently resident in Singapore (taking into account this cessation)

4

---

Number of cessations of appointments specified in Listing Rule 704 (7) or Catalist Rule 704 (6) over the past 12 months

0

---

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Chief Financial Officer

---

Role and responsibilities

Oversee the overall financial management of the Group.

---

Familial relationship with any director and/ or substantial shareholder of the listed issuer or of any of its principal subsidiaries

No

---

Shareholding interest in the listed issuer and its subsidiaries?

Yes

---

Shareholding Details

89,700 ordinary shares

---

Past (for the last 5 years)

NIL

---

Present

NIL

---